EMA Authorised: Nuwiq (simoctocog alfa) — Octapharma AB

View source ↗

Summary

The EMA authorised Nuwiq (simoctocog alfa) for Hemophilia A, with Octapharma AB as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Nuwiq (recombinant factor VIII concentrate)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Octapharma AB. Decision date: 13/10/2022